RESUMO
From July 4, 1999, when a liver transplantation program was started in Cuba, to December 30, 2007, we performed 125 procedures in 115 patients. The most frequent reasons for transplantation were cirrhosis caused by hepatitis C virus (29%) and alcoholic cirrhosis (17.2%). Two patients received simultaneous liver-kidney transplants. Sixty-seven patients were males, and the patient ages ranged from 12 to 74 years. The average surgical time was 6 hours, and cold ischemia time was 4 to 14 hours. The average blood consumption was 1630 mL; 2900 mL of plasma and 8 units of platelets were used in 7 cases. Immunosuppression was mainly cyclosporine, mycophenolate mofetil, and prednisone. Acute cellular rejections were treated in almost all cases with 3 doses of methylprednisolone. The most frequent complications were biliary (15%), hepatic arterial thrombosis (6%), postsurgical bleeding (8%), acute cellular rejection (20%), and ductopenic rejection (2%). The overall 1-year survival was 74.7%.
Assuntos
Transplante de Fígado/estatística & dados numéricos , Cuba , Feminino , Humanos , Imunossupressores/uso terapêutico , Hepatopatias/classificação , Hepatopatias/cirurgia , Transplante de Fígado/imunologia , Transplante de Fígado/métodos , Masculino , Complicações Pós-Operatórias/epidemiologia , Estudos RetrospectivosRESUMO
In July 1999 we began a liver transplant program that to October 2005 has included 100 liver transplants in 92 patients, eight retransplants, and two combined liver and kidney grafts. Twelve transplants were in pediatric patients, who showed a 92% survival rate in the first year. Fifty-four percent of the patients were male and 46% female. The most frequent etiologies of cirrhosis were 27% hepatitis virus C, 18% alcoholic, 13% cryptogenic, and 11% autoimmune. In 95% of the patients, we preserved the retrohepatic vena cava. The bile duct was reconstructed with a Kehr tube in 46% of patients with 31% using end-to-end suture with a tutor and 15% an end-to-end suture without a tutor. A hepaticojejunostomy was performed in 8%. The immunosuppression included cyclosporine (Neoral) or Prograf combined with mycophenolate mofetil or mycophenolate sodium and steroids. The most frequent biliary complications were local anastomosis leaks (6%) and stenosis (10%). The overall 1-year survival rate was 72%.
Assuntos
Hepatopatias/cirurgia , Transplante de Fígado/estatística & dados numéricos , Cuba , Humanos , Transplante de Rim/estatística & dados numéricos , Hepatopatias/classificação , Reoperação , Estudos Retrospectivos , Veia Cava Inferior/cirurgiaRESUMO
Mesenchymal hamartoma of the liver (MHL) is an uncommon tumour composed of architecturally abnormal bile ducts in an uncommitted myxoid stroma. Most MHL are diagnosed in childhood and few cases have been reported in adults. This report describes a case of a well defined solid mass in the right lobe of the liver in a 51 year old man. Preoperative radiological examination revealed a large completely solid mass. Biopsy showed a dense fibrous stroma with hyalinisation and some bile ducts. A provisional diagnosis of MHL was made. Surgical excision was impossible and liver transplantation was undertaken. Definitive pathology confirmed the diagnosis. Review of published reports shows this to be the fourth case of MHL treated by liver transplantation(AU)
Hamartoma mesenquimal del hígado (MHL) es un tumor poco frecuente, compuesto de arquitectura anormal de los conductos biliares no comprometidos en un estroma mixoide. MHL mayoría se diagnostican en la infancia y pocos casos han sido reportados en adultos. Este informe describe un caso de una masa sólida bien definida en el lóbulo derecho del hígado en un 51 años de edad. Preoperatorio examen radiológico reveló una gran masa sólida completamente. La biopsia mostró un estroma fibroso denso con hyalinisation y algunos conductos biliares. Se establece un diagnóstico de MHL se hizo. Extirpación quirúrgica fue imposible y se llevó a cabo el trasplante de hígado. Definitivo de patología confirmó el diagnóstico. Examen de los informes publicados muestran que este es el cuarto caso de MHL tratado por el trasplante hepático
Assuntos
Hamartoma/patologia , Hamartoma/cirurgia , Hepatopatias/patologia , Hepatopatias/cirurgia , Transplante de Fígado , Mesenquimoma/patologia , Mesenquimoma/cirurgiaRESUMO
Mesenchymal hamartoma of the liver (MHL) is an uncommon tumour composed of architecturally abnormal bile ducts in an uncommitted myxoid stroma. Most MHL are diagnosed in childhood and few cases have been reported in adults. This report describes a case of a well defined solid mass in the right lobe of the liver in a 51 year old man. Preoperative radiological examination revealed a large completely solid mass. Biopsy showed a dense fibrous stroma with hyalinisation and some bile ducts. A provisional diagnosis of MHL was made. Surgical excision was impossible and liver transplantation was undertaken. Definitive pathology confirmed the diagnosis. Review of published reports shows this to be the fourth case of MHL treated by liver transplantation.
Assuntos
Hamartoma/patologia , Hepatopatias/patologia , Transplante de Fígado , Mesenquimoma/patologia , Hamartoma/cirurgia , Humanos , Hepatopatias/cirurgia , Masculino , Mesenquimoma/cirurgia , Pessoa de Meia-IdadeRESUMO
From July 4, 1999, when a liver transplantation program was started in Cuba, to October 2003, 66 procedures had been performed in 60 patients. The most frequent reason was cirrhosis caused by hepatitis C virus (29%), and alcoholic cirrhosis (22%). Two patients received simultaneous liver-kidney transplants. Half of the patients were men. Patient ages ranged from 12 to 62 years; the average surgical time was 6 hours; and cold ischemia time was 4 to 14 hours. The average blood consumption was 2033 mL; 2900 mL of plasma and 8 units of platelets were used in 7 cases. Immunosuppression was mainly cyclosporine (Neoral), mycophenolate mofetil or azathioprine, and prednisone. Acute cellular rejections were treated in almost all cases with 3 doses of methylprednisolone. The most frequent complications were biliary (24%), hepatic arterial thrombosis (12%), post-surgical bleeding (10%), acute cellular rejection (24%), and ductopenic rejection (2%). The overall 1-year survival rate was 73.7%.